Streetbeat News

Earnings

JSPR

Jasper Therapeutics announced significant progress in its clinical trials and financial achievements. The company completed a $50 million stock offering, extending its cash runway through Q3 2025. It received regulatory clearance in the US and EU for the BEACON and SPOTLIGHT studies of briquilimab in CSU and CIndU patients, respectively, and initiated a Phase 1 trial for briquilimab in myelodysplastic syndromes. Initial data from these studies are expected in 2024. Additionally, Jasper presented promising preclinical data at the AAAAI 2024 Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:39 pm

JSPR

Jasper Therapeutics reported its fiscal year 2023 financial results, including a net loss of $64.5 million, or $6.18 per share, and a cash balance of $86.9 million. Research and development expenses were $51.8 million, while general and administrative expenses totaled $17.1 million.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:35 pm

AVDL

Avadel Pharmaceuticals' shares surged following the announcement of their Q4 revenue results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:34 pm

INDP

Indaptus Therapeutics announced positive results from the second cohort of its Phase 1 trial for Decoy 20, leading to the initiation of a multi-dose cohort. The data from the single dose cohort is expected to be published at a scientific conference in 2024.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:33 pm

NVDA

U.S. markets closed higher on Friday, led by Nvidia and a tech rally, despite a drop in ISM manufacturing PMI and consumer sentiment. Asian markets were mixed, with Japan's Nikkei reaching a record high. European markets and U.S. futures saw declines. Commodities showed mixed performance with crude oil slightly down and natural gas up. Nvidia's performance stands out due to the growing demand for artificial intelligence.

Portfolio Pulse from Akanksha Bakshi

March 04, 2024 | 12:29 pm

ENTG

Entegris has updated its Q1 FY2024 guidance, now expecting an adjusted EBITDA margin of approximately 27%-28%, an increase from the previously forecasted range of 26.5%-27.5%.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:18 pm

ENTG

Entegris has updated its Q1 FY2024 adjusted EPS guidance to $0.59-$0.64, slightly below its prior guidance of $0.60-$0.65 and in line with the consensus estimate of $0.62.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:17 pm

ENTG

Entegris has revised its Q1 FY2024 sales forecast to $755M-$775M, down from the previous guidance of $770M-$790M and below the consensus estimate of $787.03M.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:16 pm

BMR

Beamr (NASDAQ:BMR), a leader in video optimization technology, announced the launch of Beamr Cloud, a SaaS solution for high-quality video processing. In its annual shareholder letter, CEO Sharon Carmel highlighted the company's 2023 achievements, including financial results and the recent launch of Beamr Cloud in February 2024. Beamr raised $13.8 million in February 2024 to expand its video cloud services, focusing on User-Generated Content, Generative AI, IoT, and Streaming markets. The company plans to integrate AI workflows into Beamr Cloud and participate in the NVIDIA-led GTC conference on March 17th to discuss its AI integration plans.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:11 pm

TSLA

Tesla, Inc. (NASDAQ:TSLA) shares are down over 1% in premarket trading due to disappointing sales figures in China for February. The company sold 60,365 electric vehicles, marking a 15.51% sequential drop and an 18.9% year-over-year decline. This underperformance is attributed partly to the timing of the Chinese New Year holidays. Comparatively, Chinese EV startups Li Auto, Nio, XPeng, and BYD also reported declines, with Tesla's drop being less steep. Concerns are raised about Tesla's Q1 sales, with challenges noted in the U.S., China, and Europe.

Portfolio Pulse from Shanthi Rexaline

March 04, 2024 | 12:06 pm